Vistagen Receives FDA Approval for New Drug Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy VTGN?
Source: Newsfilter
- FDA Approval Milestone: Vistagen announced it has received a 'Study May Proceed' letter from the FDA, allowing further Phase 2 clinical development of refisolone nasal spray in the U.S., addressing a significant unmet need for the 75% of American women experiencing hot flashes during menopause.
- Clinical Trial Results: In a randomized, double-blind Phase 2a clinical study, refisolone demonstrated significant efficacy in reducing hot flash frequency by 80% in treated women compared to a 36% reduction in the placebo group, highlighting its potential for symptom relief.
- Safety Profile: The study reported good tolerability for refisolone with no serious drug-related adverse events, enhancing its appeal as a non-hormonal treatment option and potentially offering new hope for women seeking safer alternatives.
- Market Potential: With the development of refisolone, Vistagen's strategic positioning in women's health will be strengthened, potentially providing millions of women with a fast-acting, non-hormonal treatment option, thereby enhancing the company's competitiveness in the biopharmaceutical market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.597
Low
0.90
Averages
0.97
High
1.00
Current: 0.597
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vistagen Receives FDA Approval for New Drug Study
- FDA Approval Milestone: Vistagen announced it has received a 'Study May Proceed' letter from the FDA, allowing further Phase 2 clinical development of refisolone nasal spray in the U.S., addressing a significant unmet need for the 75% of American women experiencing hot flashes during menopause.
- Clinical Trial Results: In a randomized, double-blind Phase 2a clinical study, refisolone demonstrated significant efficacy in reducing hot flash frequency by 80% in treated women compared to a 36% reduction in the placebo group, highlighting its potential for symptom relief.
- Safety Profile: The study reported good tolerability for refisolone with no serious drug-related adverse events, enhancing its appeal as a non-hormonal treatment option and potentially offering new hope for women seeking safer alternatives.
- Market Potential: With the development of refisolone, Vistagen's strategic positioning in women's health will be strengthened, potentially providing millions of women with a fast-acting, non-hormonal treatment option, thereby enhancing the company's competitiveness in the biopharmaceutical market.
See More
Vistagen Lawsuit Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025, to apply as lead plaintiffs by March 16, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding Vistagen's drug fasedienol's development, resulting in investor losses when the true facts emerged, highlighting concerns over corporate transparency and information disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Vistagen Lawsuit Reminder for Investors
- Lawsuit Timeline: The class action lawsuit for Vistagen Therapeutics (NASDAQ: VTGN) covers the period from April 1, 2024, to December 16, 2025, with a critical deadline for lead plaintiff applications set for March 16, 2026, allowing investors to represent their peers in litigation.
- Compensation Structure: Investors joining the lawsuit can receive compensation without any upfront costs through a contingency fee arrangement, which alleviates financial burdens and encourages more affected shareholders to participate in the legal process.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record and resource advantages, prompting investors to be prudent in selecting legal counsel.
- Case Background: The lawsuit alleges that Vistagen misled investors regarding its drug fasedienol's development and commercialization, providing overly optimistic trial success forecasts while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
See More
Vistagen Lawsuit Reminder for Investors
- Lawsuit Deadline: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ: VTGN) common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, to participate in the class action and protect their rights.
- No Out-of-Pocket Fees: Investors joining the class action can receive compensation without any upfront costs through a contingency fee arrangement, which lowers the barrier for participation and allows more investors to seek justice without financial risk.
- Lawsuit Context: The lawsuit alleges that Vistagen's management provided overly optimistic projections regarding the success of its drug fasedienol while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise, which investors should consider when selecting legal counsel for their claims.
See More
Vistagen Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is facing a shareholder class action lawsuit alleging that it issued false and misleading statements regarding the risks of failure associated with its Phase 3 PALISADE-3 trial, potentially leading to significant investor losses.
- Investor Impact: Shareholders who purchased Vistagen shares between April 1, 2024, and December 16, 2025, and experienced substantial losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights, which could affect a large number of investors.
- Legal Deadline: The deadline to apply to be appointed lead plaintiff in the case is March 16, 2026, requiring investors to act promptly to secure their rights in the litigation.
- Law Firm Background: Holzer & Holzer, LLC has been dedicated to vigorous representation of shareholders since its founding in 2000, recovering hundreds of millions of dollars for defrauded investors, showcasing its expertise and influence in securities litigation.
See More
Investigation Launched into Vistagen Securities Litigation
- Investigation Initiated: Faruq & Faruq, LLP is investigating potential securities litigation against Vistagen Therapeutics, Inc., urging investors to contact them before the March 16, 2026 deadline to seek lead plaintiff status, highlighting the firm's commitment to addressing the company's legal liabilities.
- Stock Price Plunge: Following the December 17, 2025 announcement that the PALISADE-3 clinical trial failed to meet its primary efficacy endpoint, Vistagen's stock price plummeted over 81% to open at $0.88, reflecting extreme market pessimism regarding the company's future prospects.
- False Statement Allegations: The lawsuit alleges that Vistagen and its executives violated federal securities laws by failing to disclose adverse information related to fasedienol, leading investors to purchase shares at artificially inflated prices, potentially resulting in significant liability for the company.
- Investor Rights Protection: Faruq & Faruq encourages all individuals with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward to better protect investor rights and advance the litigation process.
See More
Vistagen Receives FDA Approval for New Drug Study
- FDA Approval Milestone: Vistagen announced it has received a 'Study May Proceed' letter from the FDA, allowing further Phase 2 clinical development of refisolone nasal spray in the U.S., addressing a significant unmet need for the 75% of American women experiencing hot flashes during menopause.
- Clinical Trial Results: In a randomized, double-blind Phase 2a clinical study, refisolone demonstrated significant efficacy in reducing hot flash frequency by 80% in treated women compared to a 36% reduction in the placebo group, highlighting its potential for symptom relief.
- Safety Profile: The study reported good tolerability for refisolone with no serious drug-related adverse events, enhancing its appeal as a non-hormonal treatment option and potentially offering new hope for women seeking safer alternatives.
- Market Potential: With the development of refisolone, Vistagen's strategic positioning in women's health will be strengthened, potentially providing millions of women with a fast-acting, non-hormonal treatment option, thereby enhancing the company's competitiveness in the biopharmaceutical market.
See More
Vistagen Lawsuit Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025, to apply as lead plaintiffs by March 16, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding Vistagen's drug fasedienol's development, resulting in investor losses when the true facts emerged, highlighting concerns over corporate transparency and information disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Vistagen Lawsuit Reminder for Investors
- Lawsuit Timeline: The class action lawsuit for Vistagen Therapeutics (NASDAQ: VTGN) covers the period from April 1, 2024, to December 16, 2025, with a critical deadline for lead plaintiff applications set for March 16, 2026, allowing investors to represent their peers in litigation.
- Compensation Structure: Investors joining the lawsuit can receive compensation without any upfront costs through a contingency fee arrangement, which alleviates financial burdens and encourages more affected shareholders to participate in the legal process.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record and resource advantages, prompting investors to be prudent in selecting legal counsel.
- Case Background: The lawsuit alleges that Vistagen misled investors regarding its drug fasedienol's development and commercialization, providing overly optimistic trial success forecasts while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
See More
Vistagen Lawsuit Reminder for Investors
- Lawsuit Deadline: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ: VTGN) common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, to participate in the class action and protect their rights.
- No Out-of-Pocket Fees: Investors joining the class action can receive compensation without any upfront costs through a contingency fee arrangement, which lowers the barrier for participation and allows more investors to seek justice without financial risk.
- Lawsuit Context: The lawsuit alleges that Vistagen's management provided overly optimistic projections regarding the success of its drug fasedienol while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise, which investors should consider when selecting legal counsel for their claims.
See More
Vistagen Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is facing a shareholder class action lawsuit alleging that it issued false and misleading statements regarding the risks of failure associated with its Phase 3 PALISADE-3 trial, potentially leading to significant investor losses.
- Investor Impact: Shareholders who purchased Vistagen shares between April 1, 2024, and December 16, 2025, and experienced substantial losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights, which could affect a large number of investors.
- Legal Deadline: The deadline to apply to be appointed lead plaintiff in the case is March 16, 2026, requiring investors to act promptly to secure their rights in the litigation.
- Law Firm Background: Holzer & Holzer, LLC has been dedicated to vigorous representation of shareholders since its founding in 2000, recovering hundreds of millions of dollars for defrauded investors, showcasing its expertise and influence in securities litigation.
See More
Investigation Launched into Vistagen Securities Litigation
- Investigation Initiated: Faruq & Faruq, LLP is investigating potential securities litigation against Vistagen Therapeutics, Inc., urging investors to contact them before the March 16, 2026 deadline to seek lead plaintiff status, highlighting the firm's commitment to addressing the company's legal liabilities.
- Stock Price Plunge: Following the December 17, 2025 announcement that the PALISADE-3 clinical trial failed to meet its primary efficacy endpoint, Vistagen's stock price plummeted over 81% to open at $0.88, reflecting extreme market pessimism regarding the company's future prospects.
- False Statement Allegations: The lawsuit alleges that Vistagen and its executives violated federal securities laws by failing to disclose adverse information related to fasedienol, leading investors to purchase shares at artificially inflated prices, potentially resulting in significant liability for the company.
- Investor Rights Protection: Faruq & Faruq encourages all individuals with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward to better protect investor rights and advance the litigation process.
See More
